IMMX News & Events

Immix Biopharma announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response - CR -. The NEXICART-2 CR rate is now 95% - 19 out of 20 patients -. All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed as of today for patients who have reached CR. All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month. The next NEXICART-2 update is expected late September. These results support the company's plan to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients. AL amyloidosis is a devastating disease where the immune system continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. NXC-201 has been awarded Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy by the FDA, and Orphan Drug Designation by the FDA and in the EU by the EMA.

Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by BLA submission and planned commercial launch. In addition to meeting guidance for NEXICART-2 enrollment completion and announcing topline NEXICART-2 results expected Q3 2026, Immix has onboarded chief medical officer, Richard Graydon. Graydon is a board-certified hematologist-oncologist with over 20 years of experience in clinical development, most recently at Merck (MRK).